setileuton

Setileuton (MK-0633) is a potent, orally active small molecule inhibitor of 5-lipoxygenase (5-LO) developed by Merck Sharp & Dohme for the treatment of chronic asthma. By targeting the 5-LO enzyme, setileuton blocks the biosynthesis of leukotrienes, including leukotriene B4 (LTB4), which are powerful inflammatory mediators that contribute to airway constriction and inflammation in asthmatic patients. Clinical development included Phase 1 and Phase 2 trials evaluating various doses in adult and pediatric populations, including Japanese adolescent patients. Although the drug demonstrated significant improvements in lung function (FEV1) at higher doses, its development was discontinued due to an unfavorable benefit-risk profile, primarily characterized by dose-dependent elevations in liver transaminases.

Other names

setileuton